Your browser is no longer supported. Please, upgrade your browser.
Settings
MRK Merck & Co., Inc. daily Stock Chart
MRK [NYSE]
Merck & Co., Inc.
IndexDJIA S&P500 P/E34.79 EPS (ttm)1.84 Insider Own0.05% Shs Outstand2.75B Perf Week0.77%
Market Cap175.43B Forward P/E15.36 EPS next Y4.16 Insider Trans-0.40% Shs Float2.73B Perf Month-2.62%
Income5.09B PEG5.62 EPS next Q1.03 Inst Own75.40% Short Float0.68% Perf Quarter2.09%
Sales40.02B P/S4.38 EPS this Y-10.00% Inst Trans-0.07% Short Ratio2.37 Perf Half Y2.80%
Book/sh14.43 P/B4.43 EPS next Y7.47% ROA5.30% Target Price69.60 Perf Year3.17%
Cash/sh4.36 P/C14.66 EPS next 5Y6.20% ROE12.50% 52W Range58.29 - 66.80 Perf YTD8.51%
Dividend1.88 P/FCF52.09 EPS past 5Y-7.00% ROI6.40% 52W High-4.37% Beta0.83
Dividend %2.94% Quick Ratio1.20 Sales past 5Y-3.70% Gross Margin76.40% 52W Low9.59% ATR0.60
Employees68000 Current Ratio1.50 Sales Q/Q0.90% Oper. Margin15.30% RSI (14)49.25 Volatility0.78% 0.89%
OptionableYes Debt/Eq0.63 EPS Q/Q63.70% Profit Margin12.70% Rel Volume1.32 Prev Close63.75
ShortableYes LT Debt/Eq0.55 EarningsOct 27 BMO Payout100.50% Avg Volume7.82M Price63.88
Recom2.30 SMA20-0.52% SMA50-0.10% SMA2000.28% Volume10,300,435 Change0.20%
Oct-18-17Upgrade Citigroup Neutral → Buy
Aug-09-17Upgrade HSBC Securities Reduce → Hold
Jul-31-17Reiterated UBS Buy $70 → $72
Jan-13-17Initiated Bryan Garnier Buy
Jan-12-17Upgrade Piper Jaffray Neutral → Overweight
Jan-12-17Upgrade Morgan Stanley Equal-Weight → Overweight
Jan-12-17Upgrade Guggenheim Neutral → Buy
Dec-19-16Downgrade Jefferies Hold → Underperform
Oct-13-16Upgrade BofA/Merrill Neutral → Buy
Sep-09-16Reiterated Barclays Overweight $66 → $72
Aug-08-16Upgrade Credit Suisse Neutral → Outperform $73
Aug-08-16Reiterated Deutsche Bank Hold $58 → $59
Apr-06-16Initiated Societe Generale Buy $80
Jan-27-16Downgrade BofA/Merrill Buy → Neutral
Dec-01-15Upgrade Barclays Equal Weight → Overweight $64 → $66
Nov-24-15Initiated Berenberg Hold
Nov-17-15Reiterated Argus Buy $70 → $65
Jun-17-15Initiated Piper Jaffray Neutral
Apr-29-15Reiterated UBS Buy $64 → $68
Apr-29-15Reiterated Argus Buy $66 → $70
Oct-20-17 04:53PM  Merck to Shed Some U.S. Sales Reps to Cut Costs The Wall Street Journal
04:50PM  Merck's sales force restructuring means 840 jobs lost American City Business Journals
12:45PM  Merck to cut 1,800 U.S. sales jobs, add 960 in chronic care Reuters
12:42PM  Merck to cut 1,800 U.S. sales jobs, add 960 in chronic care Reuters
12:10PM  Merck to cut 1,800 U.S. sales jobs, add 960 jobs in chronic care Reuters
Oct-19-17 06:26PM  Merck cyber attack may cost insurers $275 million - Verisk's PCS Reuters
01:47PM  Merck cyber attack may cost insurers $275 mln - Verisk's PCS Reuters
01:35PM  Merck cyber attack may cost insurers $275 million: Verisk's PCS Reuters
11:47AM  3 Reasons to Stay Away From Valeant Pharmaceuticals Intl Inc Stock InvestorPlace
09:30AM  AstraZeneca's sNDA for Two Cancer Drugs Gets Priority Review Zacks
09:00AM  Merck Foundation Launches Five-Year Initiative to Improve Diabetes Care for Vulnerable and Underserved U.S. Communities Business Wire
08:01AM  See what the IHS Markit Score report has to say about Merck & Co Inc. Markit
Oct-18-17 04:21PM  What to Expect from Big Pharmas After J&J's Solid Q3 Results? Zacks
02:28PM  Merck: Is Keytruda a $16B Drug? Barrons.com
09:55AM  Merck Stock Edges Higher as Citi Forecasts Strong Sales TheStreet.com
09:07AM  Boosted By Keytruda, Citi Upgrades Merck To Buy For The First Time Ever Benzinga
09:03AM  Merck shares jump after Citi upgrade on stronger cancer drug sales CNBC
06:55AM  U.S. FDA Accepts Regulatory Submission for LYNPARZA® (olaparib) in Metastatic Breast Cancer and Grants Priority Review Business Wire
06:45AM  Mercks KEYTRUDA® (pembrolizumab) More Than Doubled Median Overall Survival Compared to Chemotherapy After Two Years of Follow Up in First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with High Levels of PD-L1 Business Wire
Oct-17-17 03:56PM  Behind Mercks Performance in 3Q17 Market Realist
Oct-16-17 12:15PM  Lost beneath headlines of five-figure drug costs pharmaceutical price growth is weakening MarketWatch
10:58AM  The Cost Of Developing Drugs Is Insane. That Paper That Says Otherwise Is Insanely Bad Forbes
Oct-14-17 10:33AM  Better Buy: AbbVie Inc. vs. Merck Motley Fool
Oct-13-17 11:41AM  Merck & Co., Inc. Value Analysis (NYSE:MRK) : October 13, 2017 Capital Cube
08:01AM  See what the IHS Markit Score report has to say about Merck & Co Inc. Markit
07:02AM  Gilead Sciences, Inc. (GILD) Stock Is Primed After Kite Pharma Buy InvestorPlace
Oct-12-17 03:30PM  Merck Will Not Seek Approval for CETP Inhibitor Anacetrapib Zacks
01:00PM  Merck Makes $3 Million Charitable Donation to Support Swim Across America Business Wire
08:26AM  Merck & Co., Inc. breached its 50 day moving average in a Bearish Manner : MRK-US : October 12, 2017 Capital Cube
06:55AM  Merck Joins with the American Liver Foundation to Educate U.S. Veterans on Chronic Hepatitis C Virus (HCV) Infection Business Wire
Oct-11-17 05:31PM  [$$] Ebola Vaccines Show Promise in New Study The Wall Street Journal
05:14PM  Merck says will not seek approval of cholesterol treatment Reuters
04:45PM  Merck Provides Update on Anacetrapib Development Program Business Wire
09:46AM  Company News For Oct 11, 2017 Zacks
Oct-10-17 12:38PM  [$$] Decoding cancer: hopes rise for a new age of precision medicine Financial Times
09:27AM  KalVista Shares Skyrocket On Merck Collaboration, Ovid Pops -- Biotech Movers TheStreet.com
09:00AM  KalVista Pharma Wins Big on Merck Collaboration 24/7 Wall St.
08:01AM  See what the IHS Markit Score report has to say about Merck & Co Inc. Markit
08:00AM  Six-year Efficacy Data for GARDASIL® 9 Presented at EUROGIN 2017 Congress Business Wire
Oct-09-17 11:34AM  The 1 Event That Sent NewLink Genetics Corporation Soaring 25% in September Motley Fool
Oct-06-17 04:10PM  Here's What's Has Happened in the HCV Space Lately Zacks
Oct-05-17 09:18AM  Roche bladder cancer drug struggles as medics focus on survival Reuters
07:37AM  Changes in Eli Lillys Valuation Market Realist
07:10AM  Featured Company News - Merck to Present Latest Data on ZEPATIER for Treatment of Chronic Hepatitis C Virus Infection at The Liver Meeting 2017 ACCESSWIRE
Oct-04-17 03:50PM  [$$] LBO Profile: GHIF Uses PE Model to Tackle Global Health Challenges The Wall Street Journal
10:01AM  Merck & Co., Inc. : MRK-US: Dividend Analysis : September 15th, 2017 (record date) : By the numbers : October 4, 2017 Capital Cube
08:00AM  The Hepatitis Drug Market Is Worse Than Wall Street Realizes Bloomberg
08:00AM  Merck Highlights Ongoing Commitment to Fighting Infectious Diseases With 40 Data Presentations at ID Week 2017 Business Wire
Oct-03-17 06:55AM  Merck to Present New Data on ZEPATIER® (elbasvir and grazoprevir) for the Treatment of Chronic Hepatitis C Virus Infection at The Liver Meeting® 2017 Business Wire
06:03AM  Good News and Bad News for Gilead Sciences: Which Carries More Weight? Motley Fool
Oct-02-17 08:40AM  Merck Drops Two HCV Combination Programs Amid Competition Zacks
Sep-30-17 12:33AM  [$$] Merck Abandons New Hepatitis C Drugs Amid Crowded Market The Wall Street Journal
Sep-29-17 04:01PM  Nike, Merck Weigh on DJIA Friday 24/7 Wall St.
01:23PM  [$$] Merck Abandons New Hepatitis C Drugs The Wall Street Journal
12:20PM  US invests $170 million in late-stage Ebola vaccines, drugs Reuters
10:40AM  Must-Know Changes to Bristol-Myers Squibbs Valuation Market Realist
09:25AM  Ligand's Captisol Deals Set to Drive Growth in the Long Run Zacks
08:05AM  Merck to stop development of hepatitis C treatments Reuters
07:09AM  Merck discontinues development program for a Hep-C treatment MarketWatch
06:55AM  New and Updated Clinical Data on Mercks KEYTRUDA® (pembrolizumab) to Be Presented at 18th World Conference on Lung Cancer Business Wire
06:55AM  Merck Discontinues MK-3682B and MK-3682C Development Programs Business Wire
Sep-28-17 09:20AM  Agenus (AGEN) Remains Focused on Drug Development Programs Zacks
09:00AM  Merck Animal Health Extends Commitment to Fighting Rabies in the Worlds Most At-Risk Regions Business Wire
Sep-27-17 09:00AM  Major Pharma Short Interest Piles On 24/7 Wall St.
08:36AM  Zacks.com featured highlights include Merck, Haemonetics, LKQ, Eastman Chemical and Honeywell International Zacks
06:45AM  Merck to Hold Third-Quarter 2017 Sales and Earnings Conference Call on October 27 Business Wire
Sep-26-17 01:27PM  Axovant Sciences (AXON) Stock Crashed Over 70%: Here's Why Zacks
Sep-25-17 10:40AM  Merck's Keytruda Gets FDA Nod for Advanced Gastric Cancer Zacks
Sep-23-17 12:44PM  This Google, Microsoft, Samsung-Targeting CCleaner Attack Sets an Insidious Trend Fortune
Sep-22-17 04:01PM  Apple, UnitedHealth Weigh on DJIA Friday 24/7 Wall St.
03:30PM  FDA Approves Mercks KEYTRUDA® (pembrolizumab) for Previously Treated Patients with Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer Whose Tumors Express PD-L1 (CPS Greater Than or Equal to 1) Business Wire
01:08PM  AstraZeneca Stock Upgraded: What You Need to Know Motley Fool
09:58AM  Pfizer-Merck KGaA Skin Cancer Drug Bavencio Gets EU Approval Zacks
08:01AM  See what the IHS Markit Score report has to say about Merck & Co Inc. Markit
06:04AM  Better Buy: Celgene Corporation vs. Merck & Co., Inc. Motley Fool
Sep-20-17 08:46PM  Pfizer and Johnson & Johnson's Brewing Brawl Gets Real Motley Fool
03:50PM  2 Important Dates for Big Pharma GuruFocus.com
01:10PM  New First Line Treatment Now Available for Canadians with Metastatic Non-Small Cell Lung Cancer CNW Group
Sep-19-17 07:00AM  Pro Baseball Hall of Famer and Cancer Survivor Mike Schmidt Joins Merck, Jim Kelly and Leading Cancer Organizations To Expand Your Cancer Game Plan To Help More People Impacted by Cancer Business Wire
Sep-18-17 10:19AM  Buy Bristol-Myers Squibb Co (BMY) Stock With No Fear InvestorPlace
09:42AM  The Top Cancer Immunotherapies Expected to Reach $1 Billion in Sales in 2017 Motley Fool
Sep-15-17 08:02AM  Dow Jones Closes at New High GuruFocus.com
Sep-13-17 02:23PM  FDA panel unanimously votes to recommend GSK shingles vaccine Reuters
08:40AM  Major Pharma Short Interest Surges 24/7 Wall St.
08:01AM  See what the IHS Markit Score report has to say about Merck & Co Inc. Markit
Sep-12-17 05:36PM  Bristol-Myers Reports Positive Results from Melanoma Study Zacks
02:20PM  Now Available in Canada: ISENTRESS® HD (raltegravir), a New Once-Daily Option, in Combination with Other Antiretroviral Agents, for the Treatment of HIV-1 Infection in Appropriate Patients CNW Group
11:13AM  Supercharge Your Portfolio With Amgen, Inc. (AMGN) Stock InvestorPlace
08:01AM  See what the IHS Markit Score report has to say about Merck & Co Inc. Markit
Sep-11-17 10:06AM  See what the IHS Markit Score report has to say about Merck & Co Inc. Markit
09:00AM  Merck Announces Findings from Phase 3 Study of KEYTRUDA® (pembrolizumab), Compared to Standard of Care, in Patients with Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Business Wire
Sep-10-17 08:45AM  Mercks KEYTRUDA® (pembrolizumab) Continues to Show Overall Survival Benefit Over Chemotherapy with Nearly Two Years Follow-Up in Previously Treated Patients with Advanced Urothelial Carcinoma, Post-Platinum Failure Business Wire
Sep-09-17 08:45AM  Progression-Free Survival Data from ECHO-202 Trial of Incytes Epacadostat in Combination with Mercks KEYTRUDA® (pembrolizumab) Underscore Durability of Response in Patients with Advanced Melanoma Business Wire
Sep-08-17 10:37AM  Inside Mercks Segment-Wise Performance in 2Q17 Market Realist
10:33AM  Mercks KEYTRUDA® (pembrolizumab) Plus Pemetrexed and Carboplatin (pem/carbo) Demonstrated Continued Benefit in Overall Response Rates and Progression-Free Survival Compared to Pem/Carbo Alone in Patients with First-Line Nonsquamous NSCLC Business Wire
09:40AM  Dow 30 Stock Roundup: UTX to Buy Rockwell Collins, Merck Secures EU Keytruda Approval Zacks
09:07AM  Behind Mercks Revenues in 2Q17 Market Realist
08:20AM  Bristol-Myers' (BMY) Opdivo's Myeloma Studies Put on Hold Zacks
08:00AM  Updated Data for Mercks KEYTRUDA® (pembrolizumab) in Patients with Advanced Gastric Cancer Across Treatment Settings to Be Presented at ESMO 2017 Congress Business Wire
07:38AM  Understanding Mercks Valuation after 2Q17 Market Realist
Merck & Co., Inc. provides healthcare solutions worldwide. It operates in four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances segments. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal and intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases. It also offers neuromuscular blocking agents; anti-bacterial products; cholesterol modifying medicines; and vaginal contraceptive products. In addition, the company offers products to prevent chemotherapy-induced and post-operative nausea and vomiting; treat brain tumors, and melanoma and metastatic non-small-cell lung cancer; prevent diseases caused by human papillomavirus; and vaccines for measles, mumps, rubella, varicella, chickenpox, shingles, rotavirus gastroenteritis, and pneumococcal diseases. Further, it offers antibiotic and anti-inflammatory drugs to treat infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, horses, and swine; vaccines for poultry; parasiticide for sea lice in salmon; and antibiotics and vaccines for fishes. Additionally, the company offers companion animal products, such as ointments; diabetes mellitus treatment for dogs and cats; anthelmintic products; fluralaner products to treat fleas and ticks in dogs; and products for protection against bites from fleas, ticks, mosquitoes, and sandflies. It has collaborationS with Aduro Biotech, Inc.; Premier Inc.; Cancer Research Technology; Corning; Pfizer Inc.; and AstraZeneca PLC. The company serves drug wholesalers and retailers, hospitals, government agencies and entities, physicians, physician distributors, veterinarians, distributors, animal producers, and managed health care providers. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
KIDDER C ROBERTDirectorMay 12Option Exercise35.195,000175,95014,317May 12 04:58 PM
KIDDER C ROBERTDirectorMay 12Sale63.545,000317,6959,317May 12 04:58 PM
Davis Robert MEVP, Global Svcs & CFOMay 09Option Exercise0.0085,8810118,031May 09 04:42 PM
AMBROSE ADELE DSr.V-P & Chief Comuns OfficerMay 09Option Exercise0.002,576023,668May 09 04:42 PM
Karachun Rita ASr. VP Fince-Global ControllerMay 09Option Exercise0.002,576017,068May 09 04:42 PM
Chattopadhyay SanatExe V-P & Pres. MMDMay 02Option Exercise0.003,092043,637May 03 09:54 AM
Gerberding Julie L.EVP Strat Comm, Gl Pub PolicyMay 02Option Exercise0.003,092046,416May 03 09:52 AM
Schechter Adam HEVP & Pres-Global Human HealthApr 03Sale63.4853,8503,418,166116,336Apr 04 06:36 PM
Karachun Rita ASr. VP Fince-Global ControllerFeb 14Sale64.732,954191,22711,675Feb 15 11:30 AM
RUSSO PATRICIA FDirectorFeb 08Option Exercise35.195,000175,95018,148Feb 09 12:52 PM
RUSSO PATRICIA FDirectorFeb 08Sale64.425,000322,12113,148Feb 09 12:52 PM
WEEKS WENDELL PDirectorFeb 06Option Exercise51.865,000259,3005,100Feb 06 03:35 PM
WEEKS WENDELL PDirectorFeb 06Sale64.515,000322,542100Feb 06 03:35 PM
WENDELL PETER CDirectorFeb 03Option Exercise32.5115,000487,65016,000Feb 06 03:35 PM
Holston Michael JEVP, General CounselFeb 03Option Exercise59.0977,9594,606,471142,239Feb 06 03:35 PM
Schechter Adam HEVP & Pres-Global Human HealthFeb 03Option Exercise34.3536,3351,248,17336,335Feb 06 03:35 PM
Cech Thomas RDirectorFeb 03Option Exercise35.195,000175,9505,100Feb 06 03:35 PM
Cech Thomas RDirectorFeb 03Sale63.425,000317,100100Feb 06 03:35 PM
Schechter Adam HEVP & Pres-Global Human HealthFeb 03Sale63.7336,3352,315,6990Feb 06 03:35 PM
Holston Michael JEVP, General CounselFeb 03Sale63.9691,9595,881,25250,280Feb 06 03:35 PM
WENDELL PETER CDirectorFeb 03Sale63.6915,000955,4061,000Feb 06 03:35 PM
FRAZIER KENNETH CChairman, President & CEONov 10Option Exercise23.45133,9203,140,424642,797Nov 10 05:29 PM
FRAZIER KENNETH CChairman, President & CEONov 10Sale65.03133,9208,709,286508,877Nov 10 05:29 PM
FRAZIER KENNETH CChairman, President & CEONov 09Option Exercise23.456,080142,576514,957Nov 10 05:29 PM
FRAZIER KENNETH CChairman, President & CEONov 09Sale65.006,080395,200508,877Nov 10 05:29 PM
Gerberding Julie L.EVP Strat Comm, Gl Pub PolicyNov 07Option Exercise41.5385,5233,551,946124,638Nov 08 11:51 AM
Gerberding Julie L.EVP Strat Comm, Gl Pub PolicyNov 07Sale60.0285,5235,133,33039,115Nov 08 11:51 AM
LAZARUS ROCHELLE BDirectorNov 02Option Exercise37.3520,000746,95024,594Nov 02 04:54 PM
WENDELL PETER CDirectorNov 02Option Exercise51.865,000259,3006,000Nov 02 04:54 PM
WENDELL PETER CDirectorNov 02Sale59.505,000297,5001,000Nov 02 04:54 PM
LAZARUS ROCHELLE BDirectorNov 02Sale59.0620,0001,181,2004,594Nov 02 04:54 PM